Commercial Credit Report for Ulisse Biomed Spa

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Ulisse Biomed Spa is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Ulisse Biomed Spa
Via Cavour 20
	UDINE, 33100 Italy	Ticker: UBMUBM

Business Summary

Ulisse Biomed Spa is an Italy-based company engaged in the healthcare biotech sector. The Company focuses on creating new and transformative diagntostic platforms and products. It creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.

(Source: 10-K405)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2023	12/31/2022	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Subsidiaries

Business Name	Address	City	State/Province	Country
Hyris Ltd	Lower Ground Floor	London		United Kingdom

Business Names

Business Name
Hyris Ltd
UBM

General Information

Number of Employees:	576	(As of 12/31/2022)
Outstanding Shares:	21,804,769	(As of 2/22/2024)
Stock Exchange:	BIT

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN